DREAM Challenge winners announced

Wednesday, September 23, 2015

Winners have been announced for the Prostate Cancer DREAM Challenge, the first research challenge in prostate cancer to marry crowdsourcing with data sharing, paving a new way to tackle key research questions about metastatic castration-resistant prostate cancer (mCRPC), an advanced form of the disease with poor outcomes.

[Read More]

Hybrigenics’ inecalcitol gets FDA Orphan designation for AML

Wednesday, August 12, 2015

Hybrigenics, a Paris-based biopharmaceutical company, has received Orphan Drug designation by the FDA for inecalcitol for the treatment of acute myeloid leukemia (AML) in the U.S. Orphan designation qualifies the sponsor of the drug for various development incentives of the Orphan Drug Act, including tax credits for qualified clinical testing.

[Read More]

Celgene, Juno collaborate on cancer and autoimmune diseases

Wednesday, July 1, 2015

Celgene, headquartered in Summit, N.J., and Seattle-based Juno Therapeutics have formed a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies.

[Read More]

TransCelerate Biopharma turns three

Monday, June 1, 2015

The name alone excites many in clinical research. It’s the first—or so far best promoted—consortium consisting only of high-level people from big biopharmaceutical companies, each vowing to be deeply “pre-competitive” with one another while trying to rework some of the redundant and wasteful practices endemic to clinical research.

[Read More]